Breaking News

U.K. July Retail Sales Rise 0.1%; Median Estimate 0.4% Increase
Tweet TWEET

Protea Announces Two Additions to Its Board of Directors

Protea Announces Two Additions to Its Board of Directors

MORGANTOWN, W. Va., Feb. 6, 2013 (GLOBE NEWSWIRE) -- Protea Biosciences Group,
Inc. ("Protea"), a leader in the field of bioanalytics, announced today that
Thijs Spoor and Josiah T. Austin have been appointed to the company's Board of
Directors.

"We are delighted to welcome Thijs Spoor and Josiah Austin to our Board. Both
men bring important skill sets and a wealth of experience to our company,"
stated Stephen Turner, Protea's CEO. "Their knowledge and relationships within
the Biotech and Financial communities will help accelerate Protea's growth and
development."

Thijs Spoor is currently Chairman of the Board, CEO & President of
FluoroPharma Medical, Inc. (OTCQB:FPMI). Mr. Spoor previously held the title
of CFO for Sunstone BioSciences and worked as a strategy consultant at Oliver
Wyman focusing on helping pharmaceutical and medical device companies. Mr.
Spoor has also been an equity research analyst at J.P. Morgan and Credit
Suisse covering the Biotechnology and Medical Device industries. Mr. Spoor has
also worked in the pharmaceutical industry spending 10 years with Amersham /
GE Healthcare where he held various operating and strategy roles.

Mr. Spoor holds a Nuclear Pharmacy degree from the University of Toronto as
well as an M.B.A. from Columbia University with concentrations in finance and
accounting. Mr. Spoor has been a guest lecturer at Columbia Business School,
Kings College in London and the University of Newcastle in Australia.

Josiah T. Austin is currently the managing member of El Coronado Holdings,
L.L.C., a privately owned investment holding company, which invests in public
and private companies. He and his family own and operate agricultural
properties in the states of Arizona, Montana, and northern Sonora, Mexico
through El Coronado Ranch & Cattle Company, L.L.C. and other entities.

Mr. Austin previously served on the Board of Directors of Monterey Bay Bancorp
of Watsonville, California, and is a prior board member of New York Bancorp,
Inc., and North Fork Bancorporation. He became a director of Goodrich
Petroleum, Inc. in 2002 and was named to the Board of Directors of Novogen
Limited in September 2010. Mr. Austin also serves as a trustee of the Cuenca
Los Ojos Foundation Trust, a non-profit organization working to preserve and
restore the biodiversity of the borderland region between the United States
and Mexico through land protection, habitat restoration and wildlife
reintroduction.

Mr. Austin graduated from the University of Denver with a Bachelor of Science
in Finance in 1971.

About Protea Biosciences Group, Inc.

Protea is a leader in the field of bioanalytics – the identification and
characterization of proteins, metabolites, lipids, and other biomolecules,
which are the products of all living cells and life forms – technology that is
foundational for all pharmaceutical and life science research.

Forward-Looking Statements: This press release may contain certain statements
relating to future results which are forward-looking statements. These
statements are not historical facts, but instead represent only the Company's
belief regarding future events, many of which, by their nature, are inherently
uncertain and outside of the Company's control. It is possible that the
Company's actual results and financial condition may differ, possibly
materially, from the anticipated results and financial condition indicated in
these forward-looking statements. Further information concerning the Company
and its business, including factors that potentially could materially affect
the Company's financial results, are contained in the Company's filings with
the Securities and Exchange Commission. All forward-looking statements
included in this press release are made only as of the date of this press
release, and we do not undertake any obligation to publicly update or correct
any forward-looking statements to reflect events or circumstances that
subsequently occur or of which we hereafter become aware.

CONTACT: For more Information:
         Protea Biosciences Group, Inc.
         955 Hartman Run Road
         Morgantown, WV 26507
         304.284.2600
         www.proteabio.com
         stephen.turner@proteabio.com

         Investor Contact:
         Jeff Ramson, ProActive Capital Group
         646-863-6341
         jramson@proactivecapitalgroup.com

Protea Biosciences, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.